Assertio Holdings 2023 Investor Presentation

Commercial-focused pharmaceutical company with a diverse portfolio of specialty drugs across neurology, hospital, and pain/inflammation therapeutic areas. Assertio leverages a low-cost digital commercial model and generated $155.1M in net product sales in 2022 with $101.6M in adjusted EBITDA.